The impact of insurance status on the survival outcomes of patients with renal cell carcinoma

被引:8
|
作者
Li, Yan [1 ]
Zhu, Ming-Xi [2 ]
Zhang, Bing [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 4, Dept Anesthesiol, Yiyuan St 37, Harbin, Peoples R China
[2] Hainan Med Univ, Sch Basic Med & Life Sci, Dept Anat, Haikou, Hainan, Peoples R China
关键词
Adult; cancer-specific survival (CSS); renal cell carcinoma (RCC); Surveillance; Epidemiology and End Results database (SEER database); insurance status; HEALTH-INSURANCE; CANCER STAGE; ASSOCIATION; ADULTS; DIAGNOSIS; MORTALITY; RISK; CARE;
D O I
10.21037/tau-20-1045
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Background: The impact of insurance status on renal cell carcinoma (RCC) patient survival is unclear. In this study, we investigated the effects of insurance status on the survival outcomes of RCC patients in the United States of America. Methods: Data of patients diagnosed with RCC between 2007 and 2014 were obtained from the Surveillance, Epidemiology and End Results (SEER) database, a large national database including statistics on cancer patients. The Kaplan-Meier method and Cox regression analysis were used to determine the influence of insurance status on cancer-specific survival (CSS). Results: A total of 30,951 eligible RCC patients were identified. Of these patients, 25,493 (82.37%) were insured, 3,959 (12.79%) had any Medicaid coverage, and 1,499 (4.84%) were uninsured. Kaplan-Meier analysis revealed that insurance status was associated with better CCS (P<0.001). The 5-year CSS rates of patients with insurance, any Medicaid, and no insurance were 88.3%, 82.6%, and 82.7%, respectively. Multivariate Cox regression analysis showed that patients with any Medicaid had poorer CSS than insured patients [hazard ratio (HR), 1.222; 95% confidence interval (CI), 1.100-1.357]. Stratified analysis revealed that at localized tumor stage and at regional tumor stage or among white patients, any Medicaid insurance was an independent predictor of an unfavorable survival outcome. Conclusions: Among the RCC patients in this study, individuals with insurance experienced improved CSS while individuals with any Medicaid tended to suffer worse survival outcomes.
引用
收藏
页码:1678 / 1690
页数:13
相关论文
共 50 条
  • [41] Impact of insurance status on outcomes in melanoma
    Buckley, J.
    Wallis, L.
    Seifi, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : B5 - B5
  • [42] IMPACT OF RENAL VEIN INVASION ON THE OUTCOMES IN PATIENTS WITH RENAL CELL CARCINOMA AND CAVAL TUMOR THROMBUS
    Isharwal, Sudhir
    Zabell, Joseph
    Lundy, Scott
    Vij, Sarah
    Krshnamurthi, Venkatesh
    JOURNAL OF UROLOGY, 2017, 197 (04): : E1367 - E1367
  • [43] Clinical outcomes and survival of patients (pts) with sarcomatoid metastatic renal cell carcinoma (smRCC).
    Tantravahi, Srinivas Kiran
    Stenehjem, David D.
    Agarwal, Archana
    Kollepara, Sri Lakshmi S.
    Batten, Julia Anne
    Ward, Michael
    Albertson, Dan
    Wang, Junfeng
    Liu, Ting
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [44] Proton-pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma
    Lalani, Aly-Khan
    Mckay, Rana
    Lin, Xun
    Simantov, Ronit
    Kaymakcalan, Marina
    Choueiri, Toni
    BJU INTERNATIONAL, 2016, 118 : 7 - 7
  • [45] INVESTIGATION OF RACE AND ASSOCIATED SOCIOECONOMIC FACTORS IN SURVIVAL OUTCOMES FOR PATIENTS WITH RENAL CELL CARCINOMA
    Alam, Ridwan
    Rostom, Mary
    Patel, Sunil
    Woldu, Solomon
    Ged, Yasser
    Singla, Nirmish
    JOURNAL OF UROLOGY, 2022, 207 (05): : E348 - E348
  • [46] Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma
    Alam, Ridwan
    Rezaee, Michael E.
    Pallauf, Maximilian
    Elias, Roy
    Yerrapragada, Anirudh
    Enikeev, Dmitry
    Fang, Dong
    Shariat, Shahrokh F.
    Woldu, Solomon L.
    Ged, Yasser M. A.
    Singla, Nirmish
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (11) : 460.e1 - 460.e9
  • [47] Association of Corticosteroids With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab
    Lefort, Felix
    Dalban, Cecile
    Gross-Goupil, Marine
    Laguerre, Brigitte
    Chabaud, Sylvie
    Escudier, Bernard
    Albiges, Laurence
    JAMA ONCOLOGY, 2023, 9 (09) : 1295 - 1298
  • [48] The effect of antioxidant status on overall survival in renal cell carcinoma
    Pavlovic, Ivan
    Pejic, Snezana
    Radojevic-Skodric, Sanja
    Todorovic, Ana
    Stojiljkovic, Vesna
    Gavrilovic, Ljubica
    Popovic, Natasa
    Basta-Jovanovic, Gordana
    Dzamic, Zoran
    Pajovic, Snezana B.
    ARCHIVES OF MEDICAL SCIENCE, 2020, 16 (01) : 94 - 101
  • [49] Genomic alterations in metastatic renal cell carcinoma (mRCC): Impact on survival and clinical outcomes.
    King, Jennifer
    Hassoun, Rebecca
    Althouse, Sandra K.
    Fausel, Christopher A.
    Schneider, Bryan P.
    Logan, Theodore F.
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [50] SQUAMOUS CELL CARCINOMA OF THE RENAL PELVIS: TREATMENT IMPACT AND SURVIVAL OUTCOMES IN THE NATIONAL CANCER DATABASE
    Christopher, Connors
    Olamide, Omidele
    Nir, Tomer
    Micah, Levy
    Reza, Mehrazin
    Ketan, Badani
    John, Sfakianos
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S2 - S3